Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Ortho Biotech, Inc.
Genentech
Information provided by (Responsible Party):
John Carpenter, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00635050
First received: March 6, 2008
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

This study will evaluate the rate of response to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive (T2,T3, Nany, M0) breast carcinoma. Also, the study will evaluate the clinical and subclinical cardiotoxic effect(s) of this regimen, assess how feasible and safe the study is. Survival without any progression of disease will also be calculated.

A regimen of chemotherapy will be given to replicate the high rate of response in patients with locally advanced breast cancer. Doxil will substitute the normally given doxorubicin. It is expected that the low effect or minimal effect of Doxil on cardiac function will minimize any additional risk of cardiotoxicity from Avastin. It is expected that clinical and subclinical rates of cardiotoxicity will be very low at the total doses to be given in this clinical trial.


Condition Intervention Phase
Invasive Breast Cancer
Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer Using Sequential Doxil, Paclitaxel, and Cyclophosphamide With Concurrent Avastin

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • The primary endpoint will be the rate of achievement of complete pathological response, to be determined by findings at surgery, i.e., segmental or total mastectomy. [ Time Frame: After completion of at least 8 of the 9 chemotherapy doses. ] [ Designated as safety issue: No ]
    Frequency and proportion will be used to report the overall complete pathological response rate.


Secondary Outcome Measures:
  • Evaluate clinical and subclinical cardiotoxicity [ Time Frame: Patients who receive any treatment drugs will be included for toxicity evaluation including cardiotoxicity. ] [ Designated as safety issue: Yes ]
    The change in left ventricular ejection fraction (LVEF) measurements from baseline to end of therapy will be used as well as clinical evaluations of cardiac toxicities.

  • Assess toxicities of regimen including hand foot syndrome [ Time Frame: Patients who receive any treatment drugs will be included for toxicity evaluation ] [ Designated as safety issue: Yes ]
    Patients who receive any treatment drugs will be included for toxicity evaluation. Adverse events will be summarized with frequencies and proportions of study participants exhibiting adverse events. The severity of adverse events (none, mild, moderate, severe) and their relationship to the study product will be presented.

  • Calculate progression free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Progression free survival (PFS) will be defined as survival without local recurrence of breast cancer and without the development of distant metastasis. Death from any cause will be included as an event. The Kaplan-Meier nonparametric method will be used to estimate progression free survival.


Enrollment: 32
Study Start Date: March 2008
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Doxil, Paclitaxel, Cyclophosphamide + Avastin
Two staged phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil, paclitaxel and cyclophosphamide with concurrent Avastin in patients with locally advanced invasive breast cancer.
Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin

Regimen A: Sequential Doxil 25 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses, then by cyclophosphamide 600 mg/M 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 weeks will be given concurrently with all 3 agents. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin at the same dose equivalent beginning 6-8 weeks after definitive operation.

Regimen B: Sequential Doxil 30 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses, then by cyclophosphamide 600 mg/m 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 weeks will be given concurrently with all 3 agents. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin at the same dose equivalent beginning 6-8 weeks after definitive operation.

Other Name: Bevacizumab (Avastin)

Detailed Description:

In this trial, an attempt will be made to replicate the high rate of complete pathological response in patients with locally advanced breast cancer with a regimen in which Doxil is substituted for conventional doxorubicin. We expect that the low or minimal effect on cardiac function produced by Doxil will minimize any additional risk of cardiotoxicity from Avastin. We will also measure left ventricular ejection fractions before and after treatment to see if the substantial rate of subclinical cardiotoxicity reported by Swain et al5 and Perez et al7 can be avoided. The reported rates of cardiotoxicity after treatment with relatively high doses of Doxil are substantially lower than those of doxorubicin; few data are available to estimate the rate of cardiotoxicity of Doxil in patients treated with only about 100 mg/m2 total accumulated dose, the dose to be utilized here. The drug has been used in a few patients in the primary systemic therapy setting, with no reported clinical cardiotoxicity.

The expectation is that clinical and subclinical rates of cardiotoxicity will be very low or negligible at the total doses to be used here.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed, measurable, invasive breast carcinoma T >2cm, Nany, M0.
  • Patients with node-negative, ER or PR-positive tumors ≤4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible.
  • 19 years of age or greater
  • Known ER, PR and HER-2 status (FISH assay to be done on specimens with 2+ or 3+ immunohistochemical staining for HER-2): patients with gene amplification on FISH study will be considered to be HER-2 positive. Patients for this study must be FISH negative if immunohistochemical stain is 2+ or 3+ positive; patients with negative, 0 or 1+ immunohistochemical stain for HER-2 are eligible.
  • Known axillary nodal status: aspiration cytology or biopsy
  • Documented menopausal status premenopausal (having menstrual periods or FSH <35) or postmenopausal (≥12 months since last menstrual period with intact uterus and at least one ovary or FSH ≥35 or previous bilateral oophorectomy
  • Non-pregnant if premenopausal (negative serum or urine pregnancy test within 7 days of starting chemotherapy) and not breast feeding
  • Patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
  • Life expectancy of less than 12 weeks
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
  • Pregnant or lactating women.
  • History of cardiac disease, with New York Heart Association Grade II or greater or clinical evidence of congestive heart failure.
  • Serious comorbid medical conditions which would impair the ability to receive chemotherapy on time
  • Previous invasive cancer within the last 5 years
  • Altered mental status or dementia which would interfere with understanding of informed consent and ability to comply with study and follow-up procedures.
  • Hypersensitivity to Doxil, doxorubicin, cyclophosphamide, cremaphore (contained in teniposide, cyclosporine, and vitamin K), or to any component of Avastin
  • Inadequately controlled hypertension (defined as blood pressure of >150/100 mmHg on antihypertensive medication)
  • Unstable angina pectoris
  • History of myocardial infarction or unstable angina within 12 months prior to beginning therapy
  • History of stroke or TIA at any time
  • Clinically significant vascular (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis, aortic dissection) or peripheral vascular disease with 6 months prior to beginning therapy
  • History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) within 1 month prior to beginning therapy
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to beginning therapy or anticipation of need for major surgical procedure during the course of the study
  • Patients must have a 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. The method used at baseline must be used for later monitoring.
  • No distant metastases on bone scan and on CT scans of chest and abdomen (no metastasis on optional PET scan is an acceptable alternative; if PET scan is done for any reason it must show no evidence of distant metastasis). Baseline PET scan is recommended but not required for all patients.
  • No CNS metastasis
  • Hbg ≥9 gm, platelets ≥100,000, granulocytes ≥1000, total or direct bilirubin ≤1.2, creatinine ≤2.0 and urine protein:creatinine ratio <1.0
  • No prior chemotherapy or radiotherapy and ≤4 weeks of prior antiestrogen or aromatase inhibitor therapy
  • No concomitant hormone replacement (i.e. estrogen or progestin) therapy
  • PS less than or equal to one

Exclusion Criteria:

  • Minor surgical procedure (excluding placement of a vascular access device) such as fine needle aspiration or core needle biopsy within 7 days of beginning therapy
  • Urine protein:creatinine ratio ≥1.0 at initial screening
  • Known hypersensitivity to any component of Avastin
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of beginning therapy
  • Serious, non-healing wound, active ulcer, or untreated bone fracture
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • Known CNS metastasis, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00635050

Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294 - 0104
Sponsors and Collaborators
University of Alabama at Birmingham
Ortho Biotech, Inc.
Genentech
Investigators
Principal Investigator: John Carpenter, M.D. University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: John Carpenter, MD, Professor, Medicine, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00635050     History of Changes
Other Study ID Numbers: F070824009, UAB 0493
Study First Received: March 6, 2008
Last Updated: July 1, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
Breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Bevacizumab
Doxorubicin
Paclitaxel
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents, Phytogenic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014